Pfizer and BioNTech, AstraZeneca, Moderna, Janssen, Sanofi and GSK, and CureVac. Go remembering these names because they are the companies or alliances that are currently finalizing details of the vaccine that should end the coronavirus pandemic. The big questions one asks oneself is which one is going to play you, when, and if there will be enough for you.
For now Given the urgency, there is not much choice. Each country will resort to the one that is most advanced and is safer at the time of vaccination. And at present, there are two that are leading by their recent information, that of Pfizer and BioNTech and that of AstraZeneca, which could be distributed as early as the end of December.
Behind, Moderna, Janssen, the Sanofi and GSK consortium, and CureVac continue on their way. At least, these are the ones that are going to be distributed at the European level, as they are have already reached agreements with the European Commission, but they could add me more in the future. And of all of them, of the 1,305 million doses reserved at least, Spain has between 137 and 206 million.
Conditions to know which one Spain will use
Those more than 100 million doses need a supplier, and in that sense, as has been said, both Pfizer-BioNTech, AstraZeneca, as Moderna are the top three candidates for the progress of their investigations. For now Salvador Illa, Minister of Health, already said a month ago that 3.1 million are expected from AstraZeneca for next December, so that is almost certain.
exist Determining factors such as price or ease of storage, who can decide what to bet on depending on the country. But at this time as soon as one of those three is available they will be the most adjusted to the vaccination schedule.
For the last Spaniards to be vaccinated, they probably have a greater range of possibilities from which to choose to apply the dose. For now Salvador Illa has not communicated with certainty what the criteria will be, as it is something that is under discussion in the Interterritorial Council with the autonomous communities and scientific societies. However, it has already been dropped that older people and other groups at risk and health professionals will have priority.
The price factor and other characteristics of vaccines
Leaving aside the Chinese and Russian vaccines, which are not expected to arrive anytime soon, the European Commission is focusing for the moment on those mentioned. Y Although it has been made clear from the beginning that it is not and will not be a competition, there are factors that call for opting for one or the other.
For example, Given the economic crisis that has invaded the planet, the price is decisive, although not initiallyl. And in this sense, AstraZeneca’s is the cheapest by far, since it offers two doses for 2.9 euros in total. Then there is Janssen at 8.5 euros for one dose, Sanofi at 10 euros for two doses, Pfizer at 16.5 euros for two doses, or Moderna at 21 euros for two doses.
Another important aspect is time. Pfizer and AstraZeneca intend to commercialize them already in December 2020, while the rest will be in 2021. Or, for example, the purchase contracts already established influence, since In Spain there are already 31.5 million doses of AstraZeneca and Sanofi, 23.6 million of CureVac, 21 million of Janssen and Pfizer, and only 8.4 million of Moderna. Of course, almost all of them include additional doses in the supply and Sanofi does not.